Kan Yonemori

Articles by Kan Yonemori

141 DESTINY-Breast06 Post Hoc Analysis by Physician’s Choice of Chemotherapy: Efficacy and Safety of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in Hormone Receptor–Positive, HER2-Low or -Ultralow Metastatic Breast Cancer

ByCarlos H Barrios,Aditya Bardia, MD, MPH, FASCO,Xichun Hu,Rebecca Dent, MD,Kan Yonemori,Alyssa Morgan,Giuseppe Curigliano

April 30th 2026

142 Exploratory Biomarker Analysis of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in HER2-Low/Ultralow, Hormone Receptor–Positive Metastatic Breast Cancer in DESTINY-Breast06

ByRebecca Dent, MD,Giuseppe Curigliano,Xichun Hu,Kan Yonemori,Carlos H Barrios,Alyssa Morgan,Aditya Bardia, MD, MPH, FASCO

April 30th 2026

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer

Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma

Personalized Vaccines May Have Utility Across All Lung Cancer Stages

Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma

Transmucosal Patch Yields Pathologic Responses in Non-Invasive Oral Cancer